Pfizer and BioNTech say lower dose of COVID-19 vaccine proved safe, effective in kids 5 to 11
Pfizer and BioNTech said Monday morning that its COVID-19 vaccine was shown to be "safe, well-tolerated, and showed robust neutralizing antibody responses" in children 5 to 11. The 2,268 trial participants in that age group were given two smaller doses of the Pfizer vaccine, and the "results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," Pfizer CEO Albert Bourla said in a statement.
The Food and Drug Administration has given emergency approval of the vaccine for kids 12 to 15, and full approval to Americans 16 and older.
"We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," Bourla said. "Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. — underscoring the public health need for vaccination."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Pfizer is conducting two other ongoing trials, of kids 2 to 5 and children 6 months to 2 years old, and the results for those studies could be in before the end of the year. Nearly 5.3 million children have tested positive for COVID-19 in the U.S., NBC News reports.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Will Donald Trump wreck the Brexit deal?
Today's Big Question President-elect's victory could help UK's reset with the EU, but a free-trade agreement with the US to dodge his threatened tariffs could hinder it
By Harriet Marsden, The Week UK Published
-
Marine Le Pen's fake jobs trial
The Explainer The far-right French leader could face a fine, jail time, and a five-year ban from public office if found guilty of embezzlement
By Abby Wilson Published
-
How to earn extra cash for Christmas
The Explainer The holiday season can be expensive but there are ways to bolster your festive finances
By Marc Shoffman, The Week UK Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
WHO declares mpox a global health emergency
Speed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
By Rafi Schwartz, The Week US Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published